Role of PARP in TNBC: Mechanism of inhibition, clinical applications, and resistance
Triple-negative breast cancer is a combative cancer type with a highly inflated histological
grade that leads to poor theragnostic value. Gene, protein, and receptor-specific targets …
grade that leads to poor theragnostic value. Gene, protein, and receptor-specific targets …
[HTML][HTML] Recent advancement in developing small molecular inhibitors targeting key kinase pathways against triple-negative breast cancer
R Islam, KP Yen, NNIM Rani, MS Hossain - Bioorganic & Medicinal …, 2024 - Elsevier
Triple-negative breast cancer (TNBC) stands out as the most formidable variant of breast
cancer, predominantly affecting younger women and characterized by a bleak outlook and a …
cancer, predominantly affecting younger women and characterized by a bleak outlook and a …
Genipin-crosslinked albumin nanoparticles containing neratinib and silibinin: a dual-death therapy for triple negative breast cancer
R Ghadi, PK Pandey, A Gabhale, A Wadikar… - International Journal of …, 2023 - Elsevier
Triple negative breast cancer (TNBC) cells resist chemotherapy by hijacking apoptosis.
Alternative cell death forms like ferroptosis offer new treatment options. A combined therapy …
Alternative cell death forms like ferroptosis offer new treatment options. A combined therapy …
[HTML][HTML] Small molecule agents for triple negative breast cancer: Current status and future prospects
Y Ou, M Wang, Q Xu, B Sun, Y Jia - Translational Oncology, 2024 - Elsevier
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis. The
number of cases increased by 2.26 million in 2020, making it the most commonly diagnosed …
number of cases increased by 2.26 million in 2020, making it the most commonly diagnosed …
Eupalinolide O Induces Apoptosis in Human Triple‐Negative Breast Cancer Cells via Modulating ROS Generation and Akt/p38 MAPK Signaling Pathway
Y Zhao, L Fu, J Chen, J Zhou, C Tian… - Journal of …, 2022 - Wiley Online Library
Background. Triple‐negative breast cancer (TNBC) is a subtype of breast cancer with limited
therapeutic options. Eupalinolide O (EO) was reported to inhibit tumor growth. This study is …
therapeutic options. Eupalinolide O (EO) was reported to inhibit tumor growth. This study is …
Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer
C Tian, M Wang, H Liu, J Liu, M Xu, L Ma - Irish Journal of Medical Science …, 2023 - Springer
Objective Pyrotinib is a novel EGFR/HER2 dual tyrosine kinase inhibitor developed in
China, while its role in neoadjuvant therapy of HER2-positive (HER2+) breast cancer lacks …
China, while its role in neoadjuvant therapy of HER2-positive (HER2+) breast cancer lacks …
Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery
Y Liu, L Zheng, X Cai, X Zhang, Y Ye - Frontiers in Cardiovascular …, 2023 - frontiersin.org
Cancer treatment has been gradually shifting from non-specific cytotoxic agents to
molecularly targeted drugs. Breast cancer (BC), a malignant tumor with one of the highest …
molecularly targeted drugs. Breast cancer (BC), a malignant tumor with one of the highest …
Quantification of EGFR-HER2 heterodimers in HER2-overexpressing breast cancer cells using liquid-phase electron microscopy
DB Peckys, D Gaa, N de Jonge - Cells, 2021 - mdpi.com
Currently, breast cancer patients are classified uniquely according to the expression level of
hormone receptors, and human epidermal growth factor receptor 2 (HER2). This coarse …
hormone receptors, and human epidermal growth factor receptor 2 (HER2). This coarse …
Xianling Lianxia formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer: Effect of Xianling Lianxia formula on HER2-positive breast …
F Li, Y Wu, Y Shi, X Liu, Y Xie… - Acta Biochimica et …, 2024 - pmc.ncbi.nlm.nih.gov
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is
characterized by high invasiveness. Trastuzumab considerably improves the prognoses of …
characterized by high invasiveness. Trastuzumab considerably improves the prognoses of …
Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapies
Protein kinases are a primary focus in targeted therapy development for cancer, owing to
their role as regulators in nearly all areas of cell life. Recent strategies targeting the kinome …
their role as regulators in nearly all areas of cell life. Recent strategies targeting the kinome …